文献速递血栓与止血

艾美赛珠单抗是否应用于获得性血友病A?

Should emicizumab be used in patients with acquired hemophilia A?
PubMed 文献 · J Thromb Haemost · 2021-01-01

本文以病例讨论形式探讨艾美赛珠单抗在获得性血友病A(AHA)中的潜在应用。AHA由抗FVIII自身抗体引起,现有治疗包括旁路制剂和免疫抑制治疗。病例报告和一项系列提示艾美赛珠单抗可降低出血风险及止血治疗需求,但需前瞻性临床试验验证后方可推荐。

要点

  • 艾美赛珠单抗已获批用于先天性血友病A的出血预防。
  • 病例报告提示其可能降低AHA患者出血风险及止血治疗需求。
  • 因人群特征差异,AHA中风险获益评估困难,需前瞻性试验。

核心结论

  • 艾美赛珠单抗在AHA中的使用尚需前瞻性临床试验验证,目前不能推荐。

研究设计与样本

  • 本文为基于病例的讨论,未报告系统检索范围或样本量。

主要发现

  • 病例报告和一项系列提示艾美赛珠单抗可降低AHA患者出血风险及止血治疗需求直至缓解。
  • 艾美赛珠单抗可能允许推迟免疫抑制治疗开始或使用强度较低的方案。

关键数值与推荐

  • AHA现有管理基于旁路制剂(重组因子VIIa、活化凝血酶原复合物浓缩物)和重组猪FVIII。
  • 免疫抑制治疗(糖皮质激素、利妥昔单抗、环磷酰胺)用于抑制自身抗体形成。

临床怎么用

  • 目前不推荐在AHA中常规使用艾美赛珠单抗,应等待前瞻性临床试验结果。

局限性

  • AHA与先天性血友病人群的人口学和临床特征不同,风险获益评估困难。
  • 缺乏前瞻性临床试验数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Emicizumab is currently approved to prevent bleeding in patients with congenital hemophilia A with or without neutralizing antibodies (inhibitors) against factor VIII (FVIII). Here, we present a case-based discussion of its potential use in acquired hemophilia A (AHA), a severe bleeding disorder caused by autoantibodies against FVIII. State-of-the-art management is based on bypassing agents (recombinant factor VIIa, activated prothrombin complex concentrate) and recombinant porcine FVIII; immunosuppressive therapy (corticosteroids, rituximab, cyclophosphamide) is used to suppress autoantibody formation. Case reports and one series suggest that emicizumab can reduce the risk of bleeding and the requirement for hemostatic therapy until remission of AHA is achieved. Further, it may allow to postpone the start of immunosuppressive therapy or to use less intense regimens. However, the risk-benefit assessment of emicizumab in AHA is difficult because demographic and clinical characteristics are different compared with congenital hemophilia. Prospective clinical trials are needed before the use of emicizumab can be recommended in AHA.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Tiede A, Kemkes-Matthes B, Knöbl P, et al. Should emicizumab be used in patients with acquired hemophilia A? J Thromb Haemost. 2021. PMID: 33306259. doi:10.1111/jth.15208

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。